Professor of Medicine
Medical University of South Carolina
John W. Gnann, Jr., M.D., FIDSA, is a specialist in Infectious Diseases of adults whose research is focused on clinical virology. Dr. Gnann has over 25 years of experience in the design, implementation, and analysis of large-scale clinical trials of investigational antiviral drugs. He has a long-standing interest in HIV disease, particularly development of antiretroviral therapy and management of opportunistic infections. Previously at the University of Alabama at Birmingham (UAB), he was an active investigator in the Center for AIDS Research (CFAR) clinical core, with a focus on HIV vaccine trials conducted through the HVTN and with the UAB AIDS Clinical Trials Group (ACTG), with a focus on investigational antiretroviral drugs. Dr. Gnann has led investigations of novel therapies for DNA viruses (HSV, VZV, CMV), opportunistic infections in immunocompromised hosts (BKV), respiratory viruses (influenza, RSV), and epidemic vector-borne viruses (hantavirus, WNV). Recently-completed clinical trials include studies of long-term valacyclovir therapy for herpes simplex encephalitis, passive immunotherapy for WNV encephalitis, and cidofovir therapy for BKV nephropathy. Dr. Gnann is now a member of the ID faculty at the Medical University of South Carolina, where he is engaged in transplant infectious diseases and antimicrobial stewardship. He also serves as protocol chair for a multi-center NIH-sponsored natural history study of BK virus nephropathy in renal transplant patients.
Disclosure: GSK: Consultant, DSMB member
Wednesday, October 14, 2020
6:00pm – 8:00pm EDT
